Buy SS-31: Prescription Routes and Research Vials Compared
Checked, not rated · Updated 3 October 2026
You need a prescription to buy SS-31 legally in the US. It is sold only as Forzinity, for Barth syndrome, through AnovoRx Specialty Pharmacy, and neither AnovoRx nor the maker publishes a price (as of 3 October 2026).
Research vendors also sell research-labelled SS-31, which is not the approved medicine.
- Class
- Mitochondria-targeted tetrapeptide
- Background
- FDA-approved (accelerated approval, 2025) as Forzinity to improve muscle strength in Barth syndrome, a rare genetic mitochondrial disease.
- Human evidence
- Moderate human evidence
The evidence, risks and legal detail: my SS-31 guide. Label dosing: SS-31 dosage.
How to buy SS-31 legally
US status: FDA-approved only as Forzinity (elamipretide), under accelerated approval on 19 September 2025, to improve muscle strength in Barth syndrome patients weighing at least 30 kg.
Prescription needed? Yes. The Forzinity enrolment form, which the provider faxes to AnovoRx Specialty Pharmacy, is the prescription.
Forzinity through AnovoRx Specialty Pharmacy
Legal routeFor diagnosed Barth syndrome patients of at least 30 kg. AnovoRx is the exclusive US distributor, Forzinity is not stocked at retail pharmacies, and neither the company nor AnovoRx publishes a price.
No published price on the pages I checked.
Mito Assist patient support
Legal routeThe manufacturer's free programme checks benefits, offers co-pay help to eligible commercially insured patients and assistance to the uninsured or underinsured. The company reported 85% of its first 33 patients fully covered (30 April 2026).
No published price on the pages I checked.
Expanded Access Program
Legal routeFor Barth syndrome patients who don't meet the label, such as those under 30 kg, the treating provider can ask the company to enrol them; each request is reviewed case by case.
No published price on the pages I checked.
Compounded SS-31
Not a legal routeNo legal route. In a December 2025 warning letter, FDA listed elamipretide (SS-31) acetate among substances ineligible for 503A compounding.
No published price on the pages I checked.
Prices come from each seller's, pharmacy's or manufacturer's own page on the date shown, and they change often. "Legal status unclear" means the sources conflict or FDA has not ruled. How prescribing online works: telehealth peptide prescribing.
Research-labelled SS-31 (not the approved medicine)
A research-labelled 'SS-31' vial differs from Forzinity in law and in manufacture. Forzinity is a sterile 80 mg/mL elamipretide hydrochloride solution made under an NDA, with a label dose and safety monitoring. FDA's 24 August 2026 warning letters to Peptide Partners, Peak Performance Peptides and Royal Peptides named their 'SS-31' as unapproved new drugs, whatever the research-only label says. FDA also lists elamipretide acetate as ineligible for 503A compounding, so a compounded version is not a lawful alternative either.
Compared with the approved medicine, a research vial has not been reviewed by FDA, is labelled not for human use, and is tested only as the seller chooses.
FDA warning letters cited on this page: Warning letter: Peptide Partners LLC (24 Aug 2026); Warning letter: Peak Performance Peptides (24 Aug 2026); Warning letter: Royal Peptides LLC (24 Aug 2026); Warning letter: Darmerica LLC (8 Dec 2025).
The checklist results come from my review of each vendor and cover the whole store. A vendor can publish COAs for some products and not others.
| Vendor | Product | Price | FDA record | Names its lab | Batch COAs | Card payment | Link |
|---|---|---|---|---|---|---|---|
| Next Level PharmMy Next Level Pharm review | 10 mg vial | $30.99as of 3 October 2026 | No warning letter found | Yes | Yes | Yes | View product → |
Prices are for the product named, as shown on the vendor's own product page on the date given. They change often. Checklist results were verified on 3 October 2026. All vendors and how they compare.
What a research SS-31 COA should show
A certificate of analysis (COA) is the lab report for one batch. For SS-31, check these:
- Identity by mass spectrometry, with the expected and the measured mass side by side. For SS-31, expect about 639.8 Da (C32H49N9O5).
- Purity by HPLC for this batch, shown as a chromatogram as well as a percentage.
- A lot number that matches your vial or pack, the test date and the lab's name, so you can confirm the certificate on the lab's own site.
A purity figure does not cover sterility or bacterial endotoxins; a COA covers those only if it reports separate tests for them. Line by line: how to read a peptide COA.
Red flags when buying research SS-31
- A research vial presented as the approved medicine, or sold to you as a treatment.
- No certificate of analysis for the batch you will receive, or one without a lot number or a named lab.
- Dosing instructions or treatment claims for people on the product page.
- An FDA warning letter naming the seller. Search fda.gov before you pay.
- No way to pay with buyer protection, such as a credit card.
Common questions
Where can I buy SS-31 peptide in the USA?
The only lawful US source is Forzinity, on prescription, dispensed only by AnovoRx Specialty Pharmacy after the provider faxes the enrolment form. It is approved only for Barth syndrome in patients weighing at least 30 kg. FDA named research-sold SS-31 as an unapproved new drug in three August 2026 warning letters.
How much does elamipretide cost?
Neither the manufacturer nor AnovoRx publishes a price. Mito Assist, the manufacturer programme, offers co-pay help for eligible commercially insured patients and assistance for the uninsured or underinsured.
Has elamipretide been approved by the FDA?
Yes, as Forzinity on 19 September 2025, under accelerated approval, to improve muscle strength in Barth syndrome patients weighing at least 30 kg. Continued approval may depend on a confirmatory trial.
What is another name for SS-31 peptide?
Elamipretide, sold as Forzinity. Earlier codes were MTP-131 and Bendavia. The developer, Stealth BioTherapeutics, now trades as Mighty Therapeutics.
Can SS-31 reverse aging?
No trial has tested that. Every randomised trial was in diagnosed patients, the approval covers Barth syndrome only, and the largest controlled trial, in primary mitochondrial myopathy, missed its primary endpoints.
Is SS-31 for sale legally?
Only with a prescription. The Forzinity enrolment form, which the provider faxes to AnovoRx Specialty Pharmacy, is the prescription. Compounded SS-31: No legal route. In a December 2025 warning letter, FDA listed elamipretide (SS-31) acetate among substances ineligible for 503A compounding. This is general information, not legal advice.
Sources
- Vendor checks: my review of each vendor, on the date shown under the table. Products and prices: each vendor's own product page.
- Route prices: each seller's, pharmacy's or manufacturer's own page, on the date shown in the table.
- Legal status, class and evidence: my SS-31 guide, which cites its sources. Formula, mass and sequence: the structure record shown on that guide, checked against two sources.
- Drugs@FDA: FORZINITY NDA 215244, US Food and Drug Administration.
- FORZINITY prescribing information (2025), US Food and Drug Administration.
- FORZINITY accelerated approval letter, US Food and Drug Administration.
- FORZINITY resources: enrollment form and Mito Assist, Stealth BioTherapeutics.
- Mito Assist and AnovoRx exclusive distribution (9 Oct 2025), Stealth BioTherapeutics / PR Newswire.
- Commercial update and 2026 priorities (6 Jan 2026), Stealth BioTherapeutics / PR Newswire.
- Commercial launch update (30 Apr 2026), Mighty Therapeutics.
- Stealth is now Mighty Therapeutics, Stealth BioTherapeutics.
- FAQ: accessing FORZINITY, Barth Syndrome Foundation.
- Warning letter: Peptide Partners LLC (24 Aug 2026), US Food and Drug Administration.
- Warning letter: Peak Performance Peptides (24 Aug 2026), US Food and Drug Administration.
- Warning letter: Royal Peptides LLC (24 Aug 2026), US Food and Drug Administration.
- Warning letter: Darmerica LLC (8 Dec 2025), US Food and Drug Administration.